• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Conventional chemotherapy may be beneficial in subtypes of non-small cell lung cancer

byJeffrey CohenandAkira Shishido
April 8, 2014
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. In this meta-analysis, progression-free survival was longer with conventional chemotherapy compared to epidermal growth factor receptor inhibitor tyrosine kinase inhibitors in individuals with stage IIIB and IV non-small cell lung cancer without epidermal growth factor receptor gene mutations. 

2. In this meta-analysis, overall survival was no different with conventional chemotherapy and epidermal growth factor receptor inhibitor tyrosine kinase inhibitors in individuals with stage IIIB and IV non-small cell lung cancer without epidermal growth factor receptor gene mutations. 

Evidence Rating Level: 1 (Excellent)     

Study Rundown: In patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, tyrosine kinase inhibitors (TKI) are commonly used.  However, in NSCLC patients without EGFR mutations, there remains some controversy as to whether EGFR TKIs or conventional chemotherapies are associated with a better progression-free survival.  This study is a meta-analysis of 11 randomized controlled trials of patients with locally advanced inoperable or metastatic NSCLC without EGFR mutations comparing EGFR TKIs (erlotinib or gefitinib) with conventional chemotherapy.  The progression-free survival was significantly better for conventional chemotherapy than EGFR TKIs.  The overall survival, however, was not statistically different.

Among its strengths, the rigorous inclusion criteria used to select only well designed randomized controlled studies bolsters this meta-analysis.  A weakness of this study, however, is the relatively small number of available studies to analyze and each study’s individual weaknesses. Furthermore, toxicity was not assessed in this analysis. Nonetheless, while further study is necessary, the study supports the current use of conventional chemotherapy in NSCLC patients without EGFR mutations.

RELATED REPORTS

Royalty financing deepens exposure to small cell lung cancer revenues

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

Click to read the study, published today in JAMA

Relevant Reading: Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer

In-Depth [meta-analysis]: This study is a meta-analysis of randomized controlled trials comparing first generation EGFR TKIs (erlotinib or gefitinib) and conventional chemotherapy in individuals with inoperable locally advanced (stage IIIB) or metastatic (stage IV) NSCLC without EGFR mutations.  Eleven trials met the criteria and were included in the meta-analysis.  Ten studies reported progression-free survival.  The progression-free survival was significantly better for conventional chemotherapies than EGFR TKIs (HR 1.41, 95% CI 1.10-1.81, p<0.001).  The objective response rate (proportion of complete or partial responders among all evaluable individuals) was also increased with conventional chemotherapy (RR 1.11, 95% CI 1.02-1.21, p=0.002).  The overall survival, however, was not significantly different between individuals treated with EGFR TKIs and chemotherapy (HR 1.08, 95% CI 0.96-1.22, p=0.496).

More from this author: Risk-reduction counseling with HIV testing may not decrease rates of sexually transmitted infections, Autoantibodies may precede symptom onset in Sjögren’s Syndrome, Peer based health education program linked to reduced waist circumference, No overall change in the prevalence of obesity in the United States between 2003 and 2012, Web-based intervention insufficient for reducing drinking among students 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: chemotherapynon-small cell lung cancer
Previous Post

Access to primary care more difficult for Medicaid patients

Next Post

First trimester biomarkers screen for congenital heart defects

RelatedReports

Patient Basics: Lung Cancer Overview
Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025
Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

August 14, 2025
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

July 24, 2025
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Chronic Disease

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

July 23, 2025
Next Post
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients

First trimester biomarkers screen for congenital heart defects

Study lends support for interferon-free treatment of hepatitis C

Financial incentives improve Hep B vaccination rate among injection drug users

Spironolactone not beneficial in heart failure with preserved ejection fraction [TOPCAT trial]

Spironolactone not beneficial in heart failure with preserved ejection fraction [TOPCAT trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rate of incident dementia and care needs among older adults with new traumatic brain injury: a population-based cohort study
  • Self-Help App for Depression in People With Intellectual Disabilities: A Randomized Clinical Trial
  • A Hybrid Chatbot to Promote Pneumococcal Vaccination Among Older Adults: A Randomized Clinical Trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.